trending Market Intelligence /marketintelligence/en/news-insights/trending/zrQ3GK-iVAff8E4XFr9c1Q2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Pieris' licensing agreement with AstraZeneca gets US antitrust clearance

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Pieris' licensing agreement with AstraZeneca gets US antitrust clearance

Pieris Pharmaceuticals Inc. said its collaboration agreement with AstraZeneca PLC cleared the Hart-Scott-Rodino Act, making way for closing the deal.

Under the agreement, AstraZeneca agreed to collaborate with Pieris to develop inhaled treatments for respiratory diseases using Pieris' Anticalin technology platform.

The collaboration includes PRS-060, Pieris' Anticalin protein targeting IL-4 receptor alpha as well as four additional therapeutic programs against undisclosed targets.

AstraZeneca will make an up-front and near-term milestone payments of $57.5 million to Pieris, along with not more than $2.1 billion in development and sales milestone payments.

For co-developed programs, Pieris is also eligible to receive increased royalties or a gross margin share of profits, depending on the level of its co-development investment.